{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:29:44Z","timestamp":1770892184464,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009510","name":"University of Hull","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.omtn.2017.07.001","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T05:30:42Z","timestamp":1499491842000},"page":"317-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"8","author":[{"given":"Hannah L.","family":"Moody","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Lind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen G.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2017.07.001_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2010.04.004","article-title":"Malignant pleural mesothelioma: the standard of care and challenges for future management","volume":"78","author":"van Meerbeeck","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.omtn.2017.07.001_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jfma.2011.08.024","article-title":"Incidentally discovered malignant mesothelioma of the tunica vaginalis","volume":"112","author":"Weng","year":"2013","journal-title":"J.\u00a0Formos. Med. Assoc."},{"key":"10.1016\/j.omtn.2017.07.001_bib3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ygyno.2004.11.014","article-title":"Primary malignant mesothelioma of the peritoneum: a clinical and immunohistochemical study","volume":"96","author":"Markaki","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omtn.2017.07.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.02.043","article-title":"Molecular and genetic changes in asbestos-related lung cancer","volume":"265","author":"Nymark","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omtn.2017.07.001_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.critrevonc.2012.03.001","article-title":"The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma","volume":"84","author":"Linton","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.omtn.2017.07.001_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.lungcan.2015.06.018","article-title":"Second line therapy in malignant pleural mesothelioma: a systematic review","volume":"89","author":"Buikhuisen","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.omtn.2017.07.001_bib7","doi-asserted-by":"crossref","first-page":"e0134180","DOI":"10.1371\/journal.pone.0134180","article-title":"MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma","volume":"10","author":"Bibby","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2017.07.001_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1469-185X.2008.00061.x","article-title":"The roles of microRNA in cancer and apoptosis","volume":"84","author":"Lynam-Lennon","year":"2009","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"10.1016\/j.omtn.2017.07.001_bib9","series-title":"Epigenetic Cancer Therapy","first-page":"67","article-title":"MicroRNAs and cancer","author":"Maher","year":"2015"},{"key":"10.1016\/j.omtn.2017.07.001_bib10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.molmed.2012.06.005","article-title":"Hallmarks of cancer: of all cancer cells, all the time?","volume":"18","author":"Floor","year":"2012","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtn.2017.07.001_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrclinonc.2014.5","article-title":"Clinical relevance of circulating cell-free microRNAs in cancer","volume":"11","author":"Schwarzenbach","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtn.2017.07.001_bib12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2012.03.022","article-title":"Road to early detection of pancreatic cancer: attempts to utilize epigenetic biomarkers","volume":"342","author":"Fukushige","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omtn.2017.07.001_bib13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.clinbiochem.2013.03.015","article-title":"Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges","volume":"46","author":"De Guire","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.omtn.2017.07.001_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.molmed.2011.01.008","article-title":"Cancer microRNAs: from subtype profiling to predictors of response to therapy","volume":"17","author":"Chan","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtn.2017.07.001_bib15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","article-title":"Prognostic significance of\u00a0p16\/cdkn2a loss in pleural malignant mesotheliomas","volume":"453","author":"Dacic","year":"2008","journal-title":"Virchows Arch."},{"issue":"Suppl 1","key":"10.1016\/j.omtn.2017.07.001_bib16","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.lungcan.2005.03.017","article-title":"Implications of P16\/CDKN2A deletion in pleural mesotheliomas","volume":"49","author":"Ladanyi","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.omtn.2017.07.001_bib17","doi-asserted-by":"crossref","first-page":"22809","DOI":"10.1074\/jbc.M110.100354","article-title":"Pro-tumorigenic effects of miR-31 loss in mesothelioma","volume":"285","author":"Ivanov","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2017.07.001_bib18","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00109-012-0924-x","article-title":"MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma","volume":"90","author":"Lynam-Lennon","year":"2012","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.omtn.2017.07.001_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12032-014-0303-2","article-title":"Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component","volume":"31","author":"Matsumoto","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.omtn.2017.07.001_bib20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jhep.2015.03.019","article-title":"MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer","volume":"63","author":"Bae","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtn.2017.07.001_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yexmp.2015.06.014","article-title":"MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer","volume":"99","author":"Lu","year":"2015","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.omtn.2017.07.001_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1074\/jbc.M110.174045","article-title":"Oct1 is a switchable, bipotential stabilizer of repressed and inducible transcriptional states","volume":"286","author":"Shakya","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2017.07.001_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2045-824X-6-20","article-title":"Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression","volume":"6","author":"Gorden","year":"2014","journal-title":"Vasc. Cell"},{"key":"10.1016\/j.omtn.2017.07.001_bib24","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1158\/1078-0432.CCR-11-1667","article-title":"Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance","volume":"17","author":"Gotink","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2017.07.001_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/sj.bjc.6605467","article-title":"Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells","volume":"102","author":"Johansson","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omtn.2017.07.001_bib26","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bjc.2011.400","article-title":"Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin","volume":"105","author":"Giovannetti","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omtn.2017.07.001_bib27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3892\/or.2013.2429","article-title":"Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to\u00a0cisplatin in epithelioid malignant pleural mesothelioma","volume":"30","author":"Kang","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.omtn.2017.07.001_bib28","first-page":"305","article-title":"Gamma-H2AX\u2014a novel biomarker for DNA double-strand breaks","volume":"22","author":"Kuo","year":"2008","journal-title":"In\u00a0Vivo"},{"key":"10.1016\/j.omtn.2017.07.001_bib29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2133\/dmpk.24.418","article-title":"Paclitaxel-resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2","volume":"24","author":"Takano","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.omtn.2017.07.001_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2015.05.003","article-title":"Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy","volume":"20","author":"De Mattia","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.omtn.2017.07.001_bib31","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","article-title":"Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals","volume":"99","author":"Ishida","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2017.07.001_bib32","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.cellbi.2005.05.001","article-title":"Induced resistance in cells exposed to repeated low doses of H2O2 involves enhanced activity of antioxidant enzymes","volume":"29","author":"Bose Girigoswami","year":"2005","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.omtn.2017.07.001_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.freeradbiomed.2016.03.006","article-title":"Platinum anti-cancer drugs: free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effect","volume":"95","author":"Fong","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.omtn.2017.07.001_bib34","doi-asserted-by":"crossref","first-page":"e89534","DOI":"10.1371\/journal.pone.0089534","article-title":"Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2017.07.001_bib35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1078\/S0171-9335(04)70041-2","article-title":"Ultrastructure of nuclei of cisplatin-treated C6 glioma cells undergoing apoptosis","volume":"79","author":"Krajc\u00ed","year":"2000","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.omtn.2017.07.001_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0009-2797(92)90002-3","article-title":"Changes in the cytoskeleton pattern of tumor cells by cisplatin in\u00a0vitro","volume":"82","author":"K\u00f6pf-Maier","year":"1992","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.omtn.2017.07.001_bib37","doi-asserted-by":"crossref","first-page":"23287","DOI":"10.1074\/jbc.M001819200","article-title":"Characterization of ABCB9, an ATP binding cassette protein associated with lysosomes","volume":"275","author":"Zhang","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2017.07.001_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.canlet.2013.09.034","article-title":"MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9","volume":"343","author":"Dong","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omtn.2017.07.001_bib39","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1593\/neo.121094","article-title":"miR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer","volume":"14","author":"Cekaite","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.omtn.2017.07.001_bib40","first-page":"700","article-title":"Human miR-31 targets radixin and inhibits migration and invasion of glioma cells","volume":"27","author":"Hua","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.omtn.2017.07.001_bib41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2007.02.001","article-title":"Mechanisms of resistance to cisplatin and carboplatin","volume":"63","author":"Stewart","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.omtn.2017.07.001_bib42","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.bbamcr.2015.05.002","article-title":"Hyper-dependence of breast cancer cell types on the nuclear transporter Importin \u03b21","volume":"1853","author":"Kuusisto","year":"2015","journal-title":"Biochim Biophys Acta."},{"key":"10.1016\/j.omtn.2017.07.001_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drup.2010.12.002","article-title":"Drug transporters of platinum-based anticancer agents and their clinical significance","volume":"14","author":"Burger","year":"2011","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.omtn.2017.07.001_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.yexcr.2013.11.014","article-title":"KPNA7, a nuclear transport receptor, promotes malignant properties of pancreatic cancer cells in\u00a0vitro","volume":"322","author":"Laurila","year":"2014","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omtn.2017.07.001_bib45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1007521430236","article-title":"Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells","volume":"15","author":"Ouar","year":"1999","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.omtn.2017.07.001_bib46","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ygyno.2015.12.026","article-title":"Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance","volume":"140","author":"Boac","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omtn.2017.07.001_bib47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.bcp.2013.12.009","article-title":"miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells","volume":"87","author":"Pennati","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.omtn.2017.07.001_bib48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.biopha.2015.08.009","article-title":"MicroRNA-induced drug resistance in gastric cancer","volume":"74","author":"Dehghanzadeh","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omtn.2017.07.001_bib49","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1158\/1078-0432.CCR-13-2805","article-title":"Reduced expression of microRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine\/glutamate exchanger SLC7A11","volume":"20","author":"Drayton","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2017.07.001_bib50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bbrc.2006.03.002","article-title":"Examination of drug resistance activity of human TAP-like (ABCB9) expressed in yeast","volume":"343","author":"Ohashi-Kobayashi","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2017.07.001_bib51","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jtemb.2014.03.006","article-title":"The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy","volume":"31","author":"\u00d6hrvik","year":"2015","journal-title":"J.\u00a0Trace Elem. Med. Biol."},{"key":"10.1016\/j.omtn.2017.07.001_bib52","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bcp.2006.10.003","article-title":"Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells","volume":"73","author":"Zisowsky","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.omtn.2017.07.001_bib53","doi-asserted-by":"crossref","first-page":"e40717","DOI":"10.1371\/journal.pone.0040717","article-title":"Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein","volume":"7","author":"Stordal","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2017.07.001_bib54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-2407-8-175","article-title":"Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells","volume":"8","author":"Kalayda","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omtn.2017.07.001_bib55","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2014.11.010","article-title":"Simultaneous delivery of therapeutic antagomirs with paclitaxel for the management of metastatic tumors by a pH-responsive anti-microbial peptide-mediated liposomal delivery system","volume":"197","author":"Zhang","year":"2015","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.omtn.2017.07.001_bib56","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2017.07.001_bib57","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1164\/rccm.201503-0461LE","article-title":"A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma","volume":"191","author":"Kao","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.omtn.2017.07.001_bib58","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2217\/epi-2016-0035","article-title":"Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer","volume":"8","author":"Reid","year":"2016","journal-title":"Epigenomics"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117302111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117302111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:27:19Z","timestamp":1761874039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253117302111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":58,"alternative-id":["S2162253117302111"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2017.07.001","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2017.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors.","name":"copyright","label":"Copyright"}]}}